The Cardiovascular Market Outlook to 2011

The Cardiovascular Market Outlook to 2011 is a new report from Business Insights providing analysis of the current and future market for cardiovascular drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global cardiovascular market. This report offers insight into R&D trends in the cardiovascular market, including the discontinuation of key pipeline drugs such as Pfizer’s torcetrapib and atorvastatin, and the development of new drug classes including Novartis’Rasilez (aliskiren), anticipated to be the first to market direct renin inhibitor. Use this report to identify the leading cardiovascular companies to 2011 and discover the cardiovascular blockbusters of the future.

Published: January 2007
Table of Contents
Table of Contents (PDF)
Price: $2,875.00 / GBP1,437.50